Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

September 24, 2026

Vistagen Therapeutics (NASDAQ:VTGN) Faces Muted Market Sentiment as Crucial PALISADE-4 Data Looms ↗

Performance

52-Week Range 96.6% below 52-week high

0.1748

0.1752W Low 5.1452W High

1 Week 0.5% below 1-week high

0.171W Low 0.181W High

Vistagen Therapeutics, Inc. - Common Stock (VTGN) traded between $0.17 and $5.14 over the past 52 weeks and last traded at $0.17, 96.6% below its 52-week high. Over the past week it ranged between $0.17 and $0.18.

Past 12 Months

+2.8%

-33.6%

-41.7%

-70.9%

-74.3%

-95.9%

1W +$0.00

1M -$0.09

3M -$0.13

6M -$0.43

YTD -$0.50

1Y -$4.07

VTGN was -95.9% over the past year, -70.9% over six months, -74.3% year to date, +2.8% in the last week.

12 Months vs Market

VTGN

-95.9%

DIA

+12.1%

SPY

+12.1%

QQQ

+10.6%

IWM

+15.0%

Over the past 12 months VTGN returned -95.9% versus DIA (Dow) +12.1%, SPY (S&P 500) +12.1%, QQQ (Nasdaq 100) +10.6% and IWM (Russell 2000) +15.0%.

Volume & Liquidity 0.03× 3-mo avg

Today 314,460 3-mo avg 12.1M

723.1K

865.8K

12.1M

7.2M

YTD

4.7M

4.5M

VTGN most recently traded 314,460 shares against a 3-month average daily volume of 12.1M.

More News

Let's take a look at the stocks that are in motion in today's session. ↗

September 23, 2026

Via Chartmill

Discover the most active stocks in Wednesday's session. ↗

September 23, 2026

Via Chartmill

June 15, 2026

Via Chartmill

Wednesday's session: top gainers and losers ↗

September 23, 2026

Via Chartmill

Gapping stocks in Wednesday's session ↗

September 23, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

September 23, 2026

Via Chartmill

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

September 22, 2026

Vistagen to Present at Psych Congress 2026

September 10, 2026

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

August 14, 2026

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

August 06, 2026

MissionIRNewsBreaks – SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics

The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch

August 04, 2026

Via AB Newswire

These stocks are making the most noise in today's session. ↗

August 04, 2026

Via Chartmill

August 04, 2026

Via Investor Brand Network

Vistagen Appoints Douglas J. Williamson to its Board of Directors

July 31, 2026

Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗

Unusual volume stocks in Thursday's session ↗

July 02, 2026

Via Chartmill

Here are the top movers in Tuesday's session. ↗

June 30, 2026

Via Chartmill

June 30, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

June 30, 2026

Via Chartmill

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 30, 2026

From Vistagen

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

June 15, 2026

From Vistagen

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 09, 2026

From Vistagen

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

May 27, 2026

From Vistagen

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 19, 2026

From Vistagen